Mahmoud 2023 Pharmacol Res: Difference between revisions
(Created page with "{{Publication |title=Mahmoud AM, Kostrzewa M, Marolda V, Cerasuolo M, Maccarinelli F, Coltrini D, Rezzola S, Giacomini A, Mollica MP, Motta A, Paris D, Zorzano A, Marzo VD, Ro...") |
No edit summary |
||
| (5 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{Publication | {{Publication | ||
|title=Mahmoud AM, Kostrzewa M, Marolda V, Cerasuolo M, Maccarinelli F, Coltrini D, Rezzola S, Giacomini A, Mollica MP, Motta A, Paris D, Zorzano A, Marzo VD, Ronca R, Ligresti A (2023) Cannabidiol alters mitochondrial bioenergetics via VDAC1 and triggers cell death in hormone-refractory prostate cancer. | |title=Mahmoud AM, Kostrzewa M, Marolda V, Cerasuolo M, Maccarinelli F, Coltrini D, Rezzola S, Giacomini A, Mollica MP, Motta A, Paris D, Zorzano A, Marzo VD, Ronca R, Ligresti A (2023) Cannabidiol alters mitochondrial bioenergetics via VDAC1 and triggers cell death in hormone-refractory prostate cancer. https://doi.org/10.1016/j.phrs.2023.106683 | ||
|info=Pharmacol Res 189:106683. [https://pubmed.ncbi.nlm.nih.gov/36736415 PMID: 36736415 Open Access] | |info=Pharmacol Res 189:106683. [https://pubmed.ncbi.nlm.nih.gov/36736415 PMID: 36736415 Open Access] | ||
|authors=Mahmoud | |authors=Mahmoud Ali Mokhtar, Kostrzewa Magdalena, Marolda Viviana, Cerasuolo Marianna, Maccarinelli Federica, Coltrini Daniela, Rezzola Sara, Giacomini Arianna, Mollica Maria Pina, Motta Andrea, Paris Debora, Zorzano Antonio, Di Marzo Vincenzo, Ronca Roberto, Ligresti Alessia | ||
|year=2023 | |year=2023 | ||
|journal=Pharmacol Res | |journal=Pharmacol Res | ||
|abstract=In spite of the huge advancements in both diagnosis and interventions, hormone refractory prostate cancer (HRPC) remains a major hurdle in prostate cancer (PCa). Metabolic reprogramming plays a key role in PCa oncogenesis and resistance. However, the dynamics between metabolism and oncogenesis are not fully understood. Here, we demonstrate that two multi-target natural products, cannabidiol (CBD) and cannabigerol (CBG), suppress HRPC development in the TRansgenic Adenocarcinoma of the Mouse Prostate (TRAMP) model by reprogramming metabolic and oncogenic signaling. Mechanistically, CBD increases glycolytic capacity and inhibits oxidative phosphorylation in enzalutamide-resistant HRPC cells. This action of CBD originates from its effect on metabolic plasticity via modulation of VDAC1 and hexokinase II (HKII) coupling on the outer mitochondrial membrane, which leads to strong shifts of mitochondrial functions and oncogenic signaling pathways. The effect of CBG on enzalutamide-resistant HRPC cells was less pronounced than CBD and only partially attributable to its action on mitochondria. However, when optimally combined, these two cannabinoids exhibited strong anti-tumor effects in TRAMP mice, even when these had become refractory to enzalutamide, thus pointing to their therapeutical potential against PCa. | |abstract=In spite of the huge advancements in both diagnosis and interventions, hormone refractory prostate cancer (HRPC) remains a major hurdle in prostate cancer (PCa). Metabolic reprogramming plays a key role in PCa oncogenesis and resistance. However, the dynamics between metabolism and oncogenesis are not fully understood. Here, we demonstrate that two multi-target natural products, cannabidiol (CBD) and cannabigerol (CBG), suppress HRPC development in the TRansgenic Adenocarcinoma of the Mouse Prostate (TRAMP) model by reprogramming metabolic and oncogenic signaling. Mechanistically, CBD increases glycolytic capacity and inhibits oxidative phosphorylation in enzalutamide-resistant HRPC cells. This action of CBD originates from its effect on metabolic plasticity via modulation of VDAC1 and hexokinase II (HKII) coupling on the outer mitochondrial membrane, which leads to strong shifts of mitochondrial functions and oncogenic signaling pathways. The effect of CBG on enzalutamide-resistant HRPC cells was less pronounced than CBD and only partially attributable to its action on mitochondria. However, when optimally combined, these two cannabinoids exhibited strong anti-tumor effects in TRAMP mice, even when these had become refractory to enzalutamide, thus pointing to their therapeutical potential against PCa. | ||
|keywords=CBD, Hormone refractory prostate cancer, Mitochondrial bioenergetics, Phytocannabinoids, VDAC1 | |||
|editor=[[Plangger M]] | |editor=[[Plangger M]] | ||
|mipnetlab=ES Barcelona Zorzano A, IT Pozzuoli Ligresti A | |||
}} | }} | ||
{{Labeling | {{Labeling | ||
|area=Respiration | |area=Respiration | ||
|instruments=Oxygraph-2k | |diseases=Cancer | ||
|organism=Mouse | |||
|tissues=Endothelial;epithelial;mesothelial cell | |||
|preparations=Permeabilized cells | |||
|topics=ATP production | |||
|couplingstates=LEAK | |||
|pathways=N, S, NS, ROX | |||
|instruments=Oxygraph-2k, O2k-Fluorometer | |||
|additional=2023-02 | |additional=2023-02 | ||
}} | }} | ||
Latest revision as of 17:20, 6 February 2023
| Mahmoud AM, Kostrzewa M, Marolda V, Cerasuolo M, Maccarinelli F, Coltrini D, Rezzola S, Giacomini A, Mollica MP, Motta A, Paris D, Zorzano A, Marzo VD, Ronca R, Ligresti A (2023) Cannabidiol alters mitochondrial bioenergetics via VDAC1 and triggers cell death in hormone-refractory prostate cancer. https://doi.org/10.1016/j.phrs.2023.106683 |
» Pharmacol Res 189:106683. PMID: 36736415 Open Access
Mahmoud Ali Mokhtar, Kostrzewa Magdalena, Marolda Viviana, Cerasuolo Marianna, Maccarinelli Federica, Coltrini Daniela, Rezzola Sara, Giacomini Arianna, Mollica Maria Pina, Motta Andrea, Paris Debora, Zorzano Antonio, Di Marzo Vincenzo, Ronca Roberto, Ligresti Alessia (2023) Pharmacol Res
Abstract: In spite of the huge advancements in both diagnosis and interventions, hormone refractory prostate cancer (HRPC) remains a major hurdle in prostate cancer (PCa). Metabolic reprogramming plays a key role in PCa oncogenesis and resistance. However, the dynamics between metabolism and oncogenesis are not fully understood. Here, we demonstrate that two multi-target natural products, cannabidiol (CBD) and cannabigerol (CBG), suppress HRPC development in the TRansgenic Adenocarcinoma of the Mouse Prostate (TRAMP) model by reprogramming metabolic and oncogenic signaling. Mechanistically, CBD increases glycolytic capacity and inhibits oxidative phosphorylation in enzalutamide-resistant HRPC cells. This action of CBD originates from its effect on metabolic plasticity via modulation of VDAC1 and hexokinase II (HKII) coupling on the outer mitochondrial membrane, which leads to strong shifts of mitochondrial functions and oncogenic signaling pathways. The effect of CBG on enzalutamide-resistant HRPC cells was less pronounced than CBD and only partially attributable to its action on mitochondria. However, when optimally combined, these two cannabinoids exhibited strong anti-tumor effects in TRAMP mice, even when these had become refractory to enzalutamide, thus pointing to their therapeutical potential against PCa. • Keywords: CBD, Hormone refractory prostate cancer, Mitochondrial bioenergetics, Phytocannabinoids, VDAC1 • Bioblast editor: Plangger M • O2k-Network Lab: ES Barcelona Zorzano A, IT Pozzuoli Ligresti A
Labels: MiParea: Respiration
Pathology: Cancer
Organism: Mouse Tissue;cell: Endothelial;epithelial;mesothelial cell Preparation: Permeabilized cells
Regulation: ATP production Coupling state: LEAK Pathway: N, S, NS, ROX HRR: Oxygraph-2k, O2k-Fluorometer
2023-02
